Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Hematologic malignancies, particularly acute myeloid leukemia (AML), have seen significant treatment evolution.
• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has transitioned from a last resort to an integral component of AML therapy.

Purpose of the Study:

• To review key developments in allo-HSCT for AML.
• To analyze the distinct components of transplantation within a comprehensive AML treatment strategy.

Main Methods:

• Review of recent advancements in risk stratification, including molecular profiling and measurable residual disease (MRD) assessment.
• Analysis of evolving conditioning regimens and graft-versus-host disease (GVHD) prophylaxis strategies, such as post-transplant cyclophosphamide.
• Integration of chemotherapy, targeted therapy (including CAR T-cell therapy), and maintenance strategies into the transplantation context.

Main Results:

• Improved patient outcomes and expanded donor selection and transplant eligibility due to enhanced risk stratification and GVHD prophylaxis.
• Recognition of allo-HSCT as a component within a broader therapeutic plan, encompassing multiple treatment modalities.
• Need for orchestrated integration of various therapeutic elements for optimal AML management post-transplant.

Conclusions:

• Allo-HSCT is a cornerstone in modern AML treatment, benefiting from significant recent advancements.
• Optimal outcomes require a holistic approach, integrating transplantation with chemotherapy, targeted therapies, and maintenance strategies.
• Future AML management necessitates a coordinated orchestration of all therapeutic components surrounding allo-HSCT.